With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

Shankar Ra­maswamy doesn’t in­tend to re­peat the Roivant play­book that his broth­er start­ed eight years ago. In­stead, he wants to con­sol­i­date the gene ther­a­py process and be the go-to shop in a field that has rid­den a rocky road for many years.

Amid a bear mar­ket, he and his 160-em­ploy­ee biotech have reeled in a $270 mil­lion Se­ries C.

“Notwith­stand­ing the broad­er mar­ket con­di­tions, I think we are build­ing a very dif­fer­ent type of com­pa­ny that I think re­sem­bles what we’ve seen in oth­er modal­i­ties, whether it’s in mR­NA, or mon­o­clon­al an­ti­bod­ies, or RNAi tech­nolo­gies,” Ra­maswamy told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER